Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to XXXX - a first case report and short review of the literature.

@entity1 @entity227 @entity138 @entity1103 @entity6391
BACKGROUND: @entity1103 ( @entity1103 ) in @entity6391 ( @entity6391 ) has been managed in several ways as documented in the literature, with little success, though. The aim of our study was to report for the first time in literature the use of aflibercept in a @entity1 with @entity6391 and @entity1103 . CASE PRESENTATION: A 52-year-old @entity1 presented for @entity227 in his right eye. Best-corrected visual acuity (BCVA) was 3/10 in his right eye and 7/10 in his left eye. Physical examination and appropriate laboratory tests lead to the diagnosis of bilateral @entity6391 with @entity1103 . Retinal thickness in the foveal area of the right eye was 631   m. The @entity1 was treated with a single intravitreal injection of 0.05  ml/0.5  mg aflibercept. One month later, BCVA of the right eye increased to 4/10, while BCVA of the left eye was unchanged. @entity138 in the right eye decreased to 129   m. Multifocal electroretinogram response did not improve, yet peaks were better-shaped and no areas of eccentral vision were present. Three and six months after injection, these improvements were maintained. CONCLUSION: This first-reported case indicates that intravitreal aflibercept injection for addressing @entity1103 in @entity6391 seems to be an effective treatment.
